Risk of Secondary Cancers After CAR T Therapy May Be Similar to Risk After Other Cancer Treatments
PHILADELPHIA – The frequency of second primary malignancies (SPMs) arising in cancer survivors following treatment with CAR T-cell therapy...
PHILADELPHIA – The frequency of second primary malignancies (SPMs) arising in cancer survivors following treatment with CAR T-cell therapy...
Patients who would not have otherwise been candidates for surgery achieved successful resection PHILADELPHIA – Patients with liver cancer...
Awardees will receive $5,000 unrestricted cash prize PHILADELPHIA – The American Association for Cancer Research (AACR) is inviting journalists...
Margaret Foti, PhD, MD (hc), chief executive officer of the American Association for Cancer Research (AACR), has been selected...
New article in Clinical Cancer Research lists best practices, novel statistical methods, and suggestions for improving benefit-risk assessments PHILADELPHIA...
Study highlights potential benefits of broadening eligibility criteria for clinical trials PHILADELPHIA – Patients with treatment-refractory cancers who received...
Stoller will be recognized tonight at the 4th annual Sneaker Ball, hosted by former Eagle Rodney McLeod Jr. and...
Transgender or gender non-conforming cancer survivors had higher odds of most conditions compared to cisgender cancer survivors PHILADELPHIA –...
PHILADELPHIA – The MEK inhibitor trametinib (Mekinist) was an effective treatment for pediatric patients with relapsed or refractory juvenile...
HPV testing eight years after a negative result instead of the recommended five was found comparable to standard cytology...